A strategy to minimize the sensing voltage drift error in a transistor biosensor with a nanoscale sensing gate

Son, Hyun Woo; Jeun, Minhong; Choi, Jae-Won; Lee, Kwan H.

doi:10.2147/ijn.s134441

Cited by 8 publications

(5 citation statements)

References 12 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To evaluate the system's sensing performance, we investigated back gate sensing voltage shift (Δ V BG ) according to the variation of pH and compared it with the results from our previous study, in which we developed a dual‐gate thin film transistor (DTFT) biosensor to detect prostate cancer biomarkers including ANXA3 in urine . The current E‐FECS chip was fabricated based on the previous DTFT biosensor and the DMWG was modified for optimal operation in blood . The E‐FECS chip was sealed with an epoxy layer, which protects the degradation of the device for improving stability and reliability in blood samples.…”

Section: Resultsmentioning

confidence: 99%

“…[20] The current E-FECS chip was fabricated based on the previous DTFT biosensor and the DMWG was modified for optimal operation in blood. [23] The E-FECS chip was sealed with an epoxy layer, which protects the degradation of the device for improving stability and reliability in blood samples. The E-FECS chip with the DMWG showed a sensitivity of 1505 mV/pH with low error range (±3.474%), high linearity (R 2 = 0.992), and low CV value (4.48%) (Figure 1B).…”

Section: Electrical Ccsp-2 Detection System and Characterizationmentioning

confidence: 99%

See 1 more Smart Citation

A Novel Blood‐Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein‐2

et al. 2019

Self Cite

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second‐leading cause of cancer‐related mortality worldwide, which may be effectively reduced by early screening. Colon cancer secreted protein‐2 (CCSP‐2) is a promising blood marker for CRC. An electric‐field effect colorectal sensor (E‐FECS), an ion‐sensitive field‐effect transistor under dual gate operation with nanostructure is developed, to quantify CCSP‐2 directly from patient blood samples. The sensing performance of the E‐FECS is verified in 7 controls and 7 CRC samples, and it is clinically validated on 30 controls, 30 advanced adenomas, and 81 CRC cases. The concentration of CCSP‐2 is significantly higher in plasma samples from CRC and advanced adenoma compared with controls (both P < 0.001). Sensitivity and specificity for CRC versus controls are 44.4% and 86.7%, respectively (AUC of 0.67), and 43.3% and 86.7%, respectively, for advanced adenomas (AUC of 0.67). CCSP‐2 detects a greater number of CRC cases than carcinoembryonic antigen does (45.6% vs 24.1%), and the combination of the two markers detects an even greater number of cases (53.2%). The E‐FECS system successfully detects CCSP‐2 in a wide range of samples including early stage cancers and advanced adenoma. CCSP‐2 has potential for use as a blood‐based biomarker for CRC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Electrical Ccsp-2 Detection System and Characterizationmentioning

confidence: 99%

A Novel Blood‐Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein‐2

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, this value was reduced after HLA-A and MICA immobilization. The drift error reached the stable point after 5 min, as the immobilized proteins prevented the random reactivity of unwanted ions in PBS buffer to residual chemical links on the insulated gate [ 23 ].…”

Section: Resultsmentioning

confidence: 99%

Biosensors Based on Ion-Sensitive Field-Effect Transistors for HLA and MICA Antibody Detection in Kidney Transplantation

et al. 2022

View full text Add to dashboard Cite

This work demonstrates the ability of the Ion-Sensitive Field-Effect Transistor (ISFET)-based immunosensor to detect antibodies against the human leukocyte antigen (HLA) and the major histocompatibility complex class-I-related chain A (MICA). The sensing membrane of the ISFET devices was modified and functionalized using an APTES-GA strategy. Surface properties, including wettability, surface thickness, and surface topology, were assessed in each module of the modification process. The optimal concentrations of HLA and MICA proteins for the immobilization were 10 and 50 μg/mL. The dose-response curve showed a detection range of 1.98–40 µg/mL for anti-HLA and 5.17–40 µg/mL for anti-MICA. The analytical precision (%CV) was found to be 10.69% and 8.92% for anti-HLA and -MICA, respectively. Moreover, the electrical signal obtained from the irrelevant antibody was considerably different from that of the specific antibodies, indicating the specific binding of the relevant antibodies without noise interference. The sensitivity and specificity in the experimental setting were established for both antibodies (anti-HLA: sensitivity = 80.00%, specificity = 86.36%; anti-MICA: sensitivity = 86.67%, specificity = 88.89%). Our data reveal the potential of applying the ISFET-based immunosensor to the detection of relevant anti-HLA and -MICA antibodies, especially in the field of kidney transplantation.

show abstract

“…This phenomenon is not typically taken into account in prior work and may affect the results of reported BioFET devices to varying degrees. Several methods have been proposed to minimize the effects of signal drift, such as chemically modifying the gate-oxide layer of the BioFET, 43 using threshold-setting ion implantation to minimize the net charge density on the semiconductor, 44 and reducing the sampling time of the gate voltage. 41 Unfortunately, the absence of standardized benchmarking and testing methodologies for these devices creates challenges when comparing different strategies and determining whether signal modulation is genuinely caused by the binding of target analytes or if signal increases remain time-based artifacts resulting from signal drift.…”

Section: Introductionmentioning

confidence: 99%

Addressing Signal Drift and Screening for Detection of Biomarkers with Carbon Nanotube Transistors

Albarghouthi,

Semeniak,

Khanani

et al. 2024

ACS Nano

View full text Add to dashboard Cite

Electrical biosensors, including transistor-based devices (i.e., BioFETs), have the potential to offer versatile biomarker detection in a simple, low-cost, scalable, and point-of-care manner. Semiconducting carbon nanotubes (CNTs) are among the most explored nanomaterial candidates for BioFETs due to their high electrical sensitivity and compatibility with diverse fabrication approaches. However, when operating in solutions at biologically relevant ionic strengths, CNT-based BioFETs suffer from debilitating levels of signal drift and charge screening, which are often unaccounted for or sidestepped (but not addressed) by testing in diluted solutions. In this work, we present an ultrasensitive CNT-based BioFET called the D4-TFT, an immunoassay with an electrical readout, which overcomes charge screening and drift-related limitations of BioFETs. In high ionic strength solution (1X PBS), the D4-TFT repeatedly and stably detects subfemtomolar biomarker concentrations in a point-of-care form factor by increasing the sensing distance in solution (Debye length) and mitigating signal drift effects. Debye length screening and biofouling effects are overcome using a poly(ethylene glycol)-like polymer brush interface (POEGMA) above the device into which antibodies are printed. Simultaneous testing of a control device having no antibodies printed over the CNT channel confirms successful detection of the target biomarker via an on-current shift caused by antibody sandwich formation. Drift in the target signal is mitigated by a combination of: (1) maximizing sensitivity by appropriate passivation alongside the polymer brush coating; (2) using a stable electrical testing configuration; and (3) enforcing a rigorous testing methodology that relies on infrequent DC sweeps rather than static or AC measurements. These improvements are realized in a relatively simple device using printed CNTs and antibodies for a low-cost, versatile platform for the ongoing pursuit of point-of-care BioFETs.

show abstract

A strategy to minimize the sensing voltage drift error in a transistor biosensor with a nanoscale sensing gate

Cited by 8 publications

References 12 publications

A Novel Blood‐Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein‐2

A Novel Blood‐Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein‐2

Biosensors Based on Ion-Sensitive Field-Effect Transistors for HLA and MICA Antibody Detection in Kidney Transplantation

Addressing Signal Drift and Screening for Detection of Biomarkers with Carbon Nanotube Transistors

Contact Info

Product

Resources

About